The MarketWatch News Department was not involved in the creation of this content.-- The agreement aims to expand access to the therapy in Brazil; -- The Technology is for patients ...

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference ...

- Nine abstracts across Takeda’s hematology portfolio and pipeline demonstrate Takeda’s commitment to patient-centric, innovative care that aims to drive greater treatment outcomes - Includes data ...

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases. Jennifer Vidrine, ...

What if we could repair fundamental parts of our bodies? Gene therapy promises just that. It's like having a molecular mechanic that can fix or replace faulty genes, potentially curing diseases ...

Another disease-related barrier relates to the cytopenias experienced by many patients with HMs because of their disease or its treatment. Treatment of anemia and thrombocytopenia consists mainly of ...

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases. Improving end-of-life care for pediatric ...

Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...